Urea derivatives as anticancer agents.

Area of Science:

• Medicinal Chemistry
• Pharmacology
• Oncology

Background:

• Urea derivatives have emerged as a significant class of anticancer agents.
• Extensive research has focused on their synthesis, structure-activity relationships (SAR), and anticancer properties over the past decade.
• Key examples include aromatic urea derivatives like N-phenyl-N'-(2-chloroethyl)ureas (CEUs) and benzoylureas (BUs), as well as heterocyclic urea derivatives.

Purpose of the Study:

• To comprehensively review and summarize the anticancer activities of various urea derivatives.
• To highlight the mechanisms of action, including tubulin polymerization inhibition and kinase inhibition.
• To underscore the importance of understanding SAR for future drug design.

Main Methods:

• Literature review of published research on urea derivatives and their anticancer effects.
• Analysis of structure-activity relationships (SAR) for different classes of urea compounds.
• Examination of molecular targets such as tubulin, receptor tyrosine kinases (RTKs), raf kinases, protein tyrosine kinases (PTKs), and NADH oxidase.

Main Results:

• Aromatic urea derivatives (CEUs, BUs) demonstrate anticancer activity primarily through tubulin polymerization inhibition.
• Heterocyclic urea derivatives exhibit potent inhibitory activity against critical cancer-related enzymes like RTKs, raf kinases, PTKs, and NADH oxidase.
• Thiourea derivatives show broad-spectrum anticancer activity against leukemias and solid tumors.

Conclusions:

• Urea derivatives represent a promising scaffold for anticancer drug development.
• Understanding the SAR and cellular mechanisms of action is crucial for designing next-generation urea-based anticancer therapeutics.
• This review consolidates current knowledge to guide future research and drug discovery efforts.